Nalaganje...
Approval Summary: Imatinib Mesylate for One or Three Years in the Adjuvant Treatment of Gastrointestinal Stromal Tumors
On January 31, 2012, the U.S. Food and Drug Administration granted regular approval of imatinib mesylate tablets (Gleevec®; Novartis Pharmaceuticals Corporation, East Hanover, NJ) for the adjuvant treatment of adult patients following complete gross resection of Kit(+) (CD117(+)) gastrointestinal st...
Shranjeno v:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
AlphaMed Press
2012
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3399657/ https://ncbi.nlm.nih.gov/pubmed/22643537 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0109 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|